Literature DB >> 28804155

Insulin Degludec/Liraglutide.

Danial E Baker1.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The May 2017 monograph topics are brodalumab, etelcalcetide, guselkumab, ribociclib, and sirukumab. The MUE is on ribociclib.

Entities:  

Year:  2017        PMID： 28804155      PMCID： PMC5551637          DOI： 10.1177/0018578717715383

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  11 in total

Review 1.  8. Pharmacologic Approaches to Glycemic Treatment.

Authors: 
Journal:  Diabetes Care       Date:  2017-01       Impact factor: 19.112

2.  Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy.

Authors:  Christoph Kapitza; Bruce Bode; Steen Hvass Ingwersen; Lisbeth Vestergård Jacobsen; Pernille Poulsen
Journal:  J Clin Pharmacol       Date:  2015-07-14       Impact factor: 3.126

3.  Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).

Authors:  John B Buse; Tina Vilsbøll; Jerry Thurman; Thomas C Blevins; Irene H Langbakke; Susanne G Bøttcher; Helena W Rodbard
Journal:  Diabetes Care       Date:  2014-08-11       Impact factor: 19.112

4.  Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians.

Authors:  Amir Qaseem; Michael J Barry; Linda L Humphrey; Mary Ann Forciea; Nick Fitterman; Carrie Horwitch; Devan Kansagara; Robert M McLean; Timothy J Wilt
Journal:  Ann Intern Med       Date:  2017-01-03       Impact factor: 25.391

5.  Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.

Authors:  Stephen C L Gough; Bruce Bode; Vincent Woo; Helena W Rodbard; Sultan Linjawi; Pernille Poulsen; Lars H Damgaard; John B Buse
Journal:  Lancet Diabetes Endocrinol       Date:  2014-09-01       Impact factor: 32.069

6.  Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.

Authors:  Tina Vilsbøll; Jiten Vora; Henrik Jarlov; Kajsa Kvist; Lawrence Blonde
Journal:  Clin Drug Investig       Date:  2016-04       Impact factor: 2.859

7.  One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.

Authors:  S C L Gough; B W Bode; V C Woo; H W Rodbard; S Linjawi; M Zacho; P D Reiter; J B Buse
Journal:  Diabetes Obes Metab       Date:  2015-07-01       Impact factor: 6.577

8.  Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.

Authors:  H W Rodbard; B W Bode; S B Harris; L Rose; L Lehmann; H Jarlov; J Thurman
Journal:  Diabet Med       Date:  2016-10-07       Impact factor: 4.359

9.  Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.

Authors:  H W Rodbard; J B Buse; V Woo; T Vilsbøll; I H Langbakke; K Kvist; S C L Gough
Journal:  Diabetes Obes Metab       Date:  2015-11-05       Impact factor: 6.577

10.  The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial.

Authors:  Sultan Linjawi; Bruce W Bode; Louis B Chaykin; Jean-Pierre Courrèges; Yehuda Handelsman; Lucine M Lehmann; Abhishek Mishra; Richard W Simpson
Journal:  Diabetes Ther       Date:  2016-12-10       Impact factor: 2.945
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.